Associate Editor, OncLive
Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com
New Findings in Breast Cancer Trials Call for Restructuring of Disease Subtypes
July 6th 2022Gregory Vidal, MD, PhD, including the evolution of treatment options for HER2-low breast cancer, emerging antibody-drug conjugates in triple-negative disease, and the viability of HER3 as an emerging target in breast cancer
Read More
Tislelizumab Plus Chemotherapy Elicits Strong Survival Benefit in Esophageal Cancer
June 30th 2022The combination of tislelizumab and chemotherapy demonstrated a superior overall survival benefit compared with chemotherapy alone in patients with metastatic or unresectable esophageal squamous cell carcinoma
Read More
Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL
June 29th 2022Second-line lisocabtagene maraleucel provides an earlier CAR T-cell treatment option that improves survival outcomes and produces a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma, including those who are older and have comorbidities.
Read More
Teclistamab Elicits Survival Benefit vs Real-World Treatment in Multiple Myeloma
June 28th 2022Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.
Read More
Obe-cel CAR T-cell Therapy Demonstrates Promising Safety Profile in Relapsed/Refractory B- ALL
June 28th 2022Daniel DeAngelo MD, PhD, discusses the data seen with obecabtagene autoleucel as a novel treatment in the CAR T-cell arena, emphasizes unmet needs in B-cell acute lymphoblastic leukemia, and highlights important next steps in the study of obe-cel.
Read More
Successful Treatment Options Expand to Earlier Lines in RCC and Urothelial Cancer
June 23rd 2022Tian Zhang, MD, discusses the benefits of multidisciplinary collaboration, how to select the best agents for each patient, and how treatments such as radiation in RCC and bladder-sparing chemoradiation in urothelial cancer fit into the overall treatment paradigms for these diseases.
Read More
Ibrutinib Plus Bendamustine and Rituximab Prolongs PFS Benefit in Newly Diagnosed MCL
June 21st 2022Michael Wang, MD, discusses the innovative design of the SHINE trial, notes the importance of developing improved treatments for older patient populations, and highlights significant progression-free survival and safety data from the study.
Read More
Fedratinib with GI Prophylaxis Has Tolerable Safety Profile in Myelofibrosis After Prior Ruxolitinib
June 17th 2022Fedratinib was shown to be generally well tolerated in older patients with myelofibrosis who had received at least 3 months of prior ruxolitinib, according to findings from the phase 3b FREEDOM trial.
Read More
Individualized Care Informs Treatment Modality Choices in Pelvic and Sacral Ewing Carcinoma
June 17th 2022R. Lor Randall, MD, FACS, discusses the similar benefits offered by radiation and surgery, improved surgical techniques, concerns with morbidity with each approach, and the next steps surgeons and radiation therapists can take to increase patient survival in nonmetastatic pelvic and sacral Ewing carcinoma.
Read More
Hormone Therapies, ADCs Elicit Long-Term Survival Benefits Across Breast Cancer Subtypes
June 17th 2022Novel combinations with CDK4/6 inhibitors, antibody-drug conjugates, and oral selective estrogen receptor degraders are rapidly changing the treatment paradigm in hormone receptor–positive and HER2-positive breast cancer.
Read More
Epcoritamab Plus R-DHAX/C Demonstrates High Response Rates and Manageable Safety in DLBCL
June 10th 2022Epcoritamab plus rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin displayed encouraging responses in patients with relapsed/refractory diffuse large B-cell lymphoma who are eligible for autologous stem cell transplant, according to preliminary results from arm 4 of the phase 1b/2 EPCORE NHL-2 trial.
Read More
Novel Chemoimmunotherapy Combinations Build on Established Treatment Standards in Lung Cancer
June 9th 2022Lawrence E. Feldman, MD, discusses shifting standards of care in small cell lung cancer, plus the implications of the phase 3 LEAP-006 and LEAP-008 trials in non–small cell lung cancer.
Read More
Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions
June 7th 2022Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.
Read More
Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma
June 6th 2022Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.
Read More
Magrolimab Plus Azacitidine Elicits Manageable Anemia in HR-MDS
June 4th 2022Magrolimab plus azacitidine, at priming and maintenance doses, enables manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, according to results from a prospective phase 1 study (NCT03248479).
Read More
Venetoclax Plus Rituximab Continues to Demonstrate Survival and MRD Benefits in CLL
June 3rd 2022Fixed-duration venetoclax plus rituximab has shown sustained progression-free survival, overall survival, and minimal residual disease benefits vs bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, regardless of high-risk biomarkers.
Read More
Heightened Histological Focus Fosters Treatment Advances in Non-clear Cell RCC
June 1st 2022Chung-Han Lee, MD, PhD, explains the historical barriers to treatment developments in non-clear cell renal cell carcinoma; highlights the efficacy of cabozantinib plus nivolumab in patients with unclassified, translocation, papillary, and fumarate hydratase–deficient non-clear cell renal cell carcinoma; and elaborates on the need for increased molecular classification of the histologic subsets of non-clear cell renal cell carcinoma.
Read More
Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment
June 1st 2022Emerging data with novel antibody-drug conjugates such as trastuzumab deruxtecan-nxki, vic-trastuzumab duocarmazine, and disitamab vedotin are showing encouraging activity in HER2-low breast cancer.
Read More
Novel Second-line Treatments Expand Therapeutic Options in Gastrointestinal Cancers
June 1st 2022Kelsey Klute, MD, discusses the importance of frontline checkpoint inhibitors in advanced gastric cancer, the need for predictive biomarkers in hepatocellular carcinoma, and research investigating immunotherapy in HER2-negative gastric and esophagus cancer and esophagus and gastroesophageal junction cancer.
Read More
Fighting Sexual Harassment Within Oncology Begins With Authentic, Actionable Conversations
May 31st 2022Ishwaria M. Subbiah, MD, MS, brings attention to the perpetrators of sexual harassment, outlines the nuances of how these experiences affect personal wellbeing and job satisfaction, and highlights the need for accountability as a first step toward systemic change across the oncology community.
Read More
Quadruplets, Bispecific Antibodies, and CAR T-Cell Therapies Usher in Advances in Multiple Myeloma
May 27th 2022Noopur Raje, MD, reviews the benefits of quadruplet regimens in the up-front and relapsed settings, treatment options for relapsed/refractory disease, and the possibilities for combinations to minimize toxicities in those who receive CAR T-cell or bispecific antibody therapies.
Read More
CDK4/6 Inhibition and Surgery Endeavors Help Break Ground for Innovative Breast Cancer Treatments
May 18th 2022Adam M. Brufsky, MD, PhD, emphasizes the importance of tyrosine kinase inhibitors in HER2-postive breast cancer and highlights the potential benefits of local salvage radiation therapy in patients with oligometastatic or de novo stage IV breast cancer.
Read More
A Widening Scope of Treatment Options Advances Care in Bladder Cancer and RCC
May 18th 2022Mark T. Fleming, MD, reviews the use of first-line checkpoint inhibitors in bladder cancer, the efficacy of enfortumab vedotin-ejfv in urothelial cancer, and the clinical benefits of using different mechanisms of action to treat renal cell carcinoma.
Read More
Immunotherapy Plus Nadofaragene Firadenovec Could Display Synergistic Activity in NMIBC
May 17th 2022Nadofaragene firadenovec combined with immune checkpoint inhibitors such as pembrolizumab may play a synergistic role in the treatment of patients with Bacillus Calmette–Guérin-unresponsive non–muscle invasive bladder cancer.
Read More